インフルエンザワクチンの世界市場 - 2025年～2033年

インフルエンザワクチンの世界市場は2024年に84億1,000万米ドルに達し、2032年には137億5,000万米ドルに達すると予測され、予測期間2025年～2033年のCAGRは6.5%で成長する見込みです。

回答

世界のインフルエンザワクチン市場は、インフルエンザウイルスによって引き起こされる伝染性の呼吸器疾患であるインフルエンザの予防を目的としたワクチンの開発、生産、流通に特化した商業セクターを指します。この市場には様々な種類のワクチンが含まれ、主にその製剤や対象となる株によって分類されます。

ワクチンの種類には、不活化ワクチンと弱毒生ワクチンがあります。不活化ワクチンこれらのワクチンは、死滅したウイルス粒子から作られています。インフルエンザワクチンの中で最も一般的に使用され、注射によって投与されます。不活化ワクチンは、病気を引き起こすリスクなしに免疫反応を刺激するため、ほとんどの集団にとって安全な選択肢となります。

弱毒生ワクチンは、弱毒化したインフルエンザウイルスを含むワクチンで、通常、点鼻薬として投与されます。弱毒化された生ワクチンは、自然感染を忠実に模倣しているため、強固な免疫反応が得られますが、特定のハイリスク・グループには適さない場合があります。

インフルエンザ・ワクチンは、3価ワクチンと4価ワクチンの2種類に分類されます。価ワクチンは、3つのインフルエンザウイルス株（2つのA株（典型的なH1N1とH3N2）と1つのB株）に対して予防します。3価ワクチンは、インフルエンザワクチン接種の伝統的な標準となっています。

4価ワクチンは、A型2株とB型2株（各系統から1株ずつ）の計4株を標的とすることで、より広い予防効果を発揮します。このように接種範囲が拡大されると、インフルエンザシーズン中により多くの株を予防することができるため、特に有益であり、4価ワクチンはヘルスケアプロバイダーや患者からますます好まれるようになっています。このような要因が、世界のインフルエンザワクチン市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

インフルエンザ罹患率の増加

インフルエンザ罹患率の増加は、世界のインフルエンザワクチン市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予想されます。

世界保健機関（WHO）の推計によると、インフルエンザの世界の流行がワクチン需要を大きく牽引しています。WHOによると、季節性インフルエンザは毎年約300万～500万人の重症患者と29万～65万人の呼吸器疾患による死亡者を出しています。この大きな疾病負担は、効果的なワクチン接種プログラムの緊急の必要性を強調しています。

同様に、米国疾病対策予防センター（CDC）によると、2010年から2023年にかけて、インフルエンザによる疾病数は年間930万人から4,100万人、入院患者数は10万人から71万人、死亡者数は4,900人から51,000人と推定されています。この重大な健康負担に対処するため、インフルエンザ予防のために、FDAが承認した数多くのワクチンがインフルエンザシーズンごとに利用できるようになっています。

重症化と死亡率という点で、インフルエンザによる世界の負担が大きいことから、効果的なワクチン接種プログラムが緊急に必要とされています。インフルエンザワクチンの重要性に対する認識を高め、しっかりとした公衆衛生戦略を実施することで、保健当局はインフルエンザとそれに関連する合併症の発生率を低下させ、最終的に世界中の人々の健康状態を改善することを目指しています。

さらに、業界の主要企業は、このインフルエンザワクチン市場の成長を促進する重要なイニシアチブをとっています。例えば、2024年7月には、ヒト鳥インフルエンザ（H5N1）メッセンジャーRNA（mRNA）ワクチン候補の開発と入手を加速するための新たなイニシアチブが開始され、特に中低所得国（LMICs）の製造業者をターゲットとしています。

このプロジェクトは、アルゼンチンのメーカーであるSinergium Biotech社が主導し、世界保健機関（WHO）と医薬品特許プール（MPP）のmRNA技術移転プログラムを活用しています。これらの要因が世界のインフルエンザワクチン市場を活性化します。

さらに、混合ワクチン開発の成長に対する需要の高まりが、世界のインフルエンザワクチン市場の拡大に寄与しています。

製造工程に伴う高コスト

製造プロセスに関連する高コストは、世界のインフルエンザワクチン市場における重要な抑制要因です。この制約は、ワクチン製造に関わる費用全体に寄与する様々な要因から生じ、最終的には入手可能性と価格の両方に影響を与えます。

ワクチン製造施設の設立は資本集約的であり、その費用は1抗原あたり5,000万米ドルから5億米ドルに及ぶ。正確な金額は、設計の複雑さ、自動化、必要な汚染防止対策によって異なります。現行の適正製造基準（cGMP）に準拠するように設計された施設では、製品の安全性と有効性を確保するために特殊な設備とインフラが必要となり、初期投資コストを押し上げます。

これらのコストは、複雑な設備要件、人件費、原材料価格、規制遵守の必要性、投資回収期間の長さに起因します。生産技術の革新と効率の改善を通じてこれらの課題に対処することで、これらの財政的負担を軽減し、世界的にワクチンへのアクセス性を高めることができます。したがって、上記の要因が世界のインフルエンザワクチン市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • インフルエンザの発生率増加
  • 抑制要因
    • 製造プロセスに関連する高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 製品タイプ別

• 不活性化
• 生弱毒化

第7章 カテゴリー別

• 四価
• 三価

第8章 投与経路別

• 注射
• 鼻スプレー

第9章 年齢層別

• 小児
• 大人

第10章 エンドユーザー別

• 病院
• 病院
• 専門クリニック
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第13章 企業プロファイル

• Sanofi
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• GSK plc.
• Pfizer Inc.
• AstraZeneca
• CSL
• Viatris Inc.（Mylan）
• Bharat Biotech.
• SINOVAC
• Zydus Cadila Healthcare Limited
• Serum Institute of India Pvt. Ltd.

第14章 付録

The global influenza vaccine market reached US$ 8.41 billion in 2024 and is expected to reach US$ 13.75 billion by 2032, growing at a CAGR of 6.5 % during the forecast period 2025-2032.

Answer

The global influenza vaccine market refers to the commercial sector dedicated to the development, production, and distribution of vaccines designed to prevent influenza, a contagious respiratory illness caused by influenza viruses. This market encompasses various types of vaccines, which are categorized primarily based on their formulation and the strains they target.

Types of vaccines include inactivated vaccines and live attenuated vaccines. Inactivated vaccines these vaccines are made from killed virus particles. They are the most commonly used type of influenza vaccine and are administered via injection. Inactivated vaccines stimulate an immune response without the risk of causing the disease, making them a safe choice for most populations.

Live attenuated vaccines these vaccines contain weakened forms of the influenza virus and are typically administered as a nasal spray. Live attenuated vaccines can provide a robust immune response because they closely mimic natural infection, but they may not be suitable for certain high-risk groups.

Influenza vaccines are also classified by their valency, which refers to the number of virus strains they protect against trivalent vaccines and quadrivalent vaccines. Trivalent vaccines protect against three strains of the influenza virus: two A strains (typically H1N1 and H3N2) and one B strain. Trivalent vaccines have been the traditional standard for flu vaccination.

Quadrivalent vaccines offer broader protection by targeting four strains: two A strains and two B strains (one from each lineage). This expanded coverage is particularly beneficial as it helps protect against more circulating strains during flu season, making quadrivalent vaccines increasingly preferred by healthcare providers and patients alike. These factors have driven the global influenza vaccine market expansion.

Market Dynamics: Drivers & Restraints

Increasing Incidence of Influenza

The increasing incidence of influenza is significantly driving the growth of the global influenza vaccine market and is expected to drive throughout the market forecast period.

The rising global prevalence of influenza significantly drives the demand for vaccines, as highlighted by estimates from the World Health Organization (WHO). According to WHO, seasonal influenza results in approximately 3 to 5 million cases of severe illness and 290,000 to 650,000 respiratory deaths each year. This substantial burden of disease underscores the urgent need for effective vaccination programs.

Similarly, according to the U.S. Centers for Disease Control and Prevention (CDC), influenza has resulted in an estimated 9.3 million to 41 million illnesses, 100,000 to 710,000 hospitalizations, and 4,900 to 51,000 deaths annually from 2010 to 2023. To combat this significant health burden, numerous FDA-approved vaccines are available each flu season to help prevent influenza.

The significant global burden of influenza in terms of severe illness and mortality drives the urgent need for effective vaccination programs. By increasing awareness of the importance of flu vaccines and implementing robust public health strategies, health authorities aim to reduce the incidence of influenza and its associated complications, ultimately improving population health outcomes worldwide.

Furthermore, major players in the industry have key initiatives that would propel this influenza vaccine market growth. For instance, in July 2024, a new initiative was launched to accelerate the development and accessibility of human avian influenza (H5N1) messenger RNA (mRNA) vaccine candidates, specifically targeting manufacturers in low- and middle-income countries (LMICs).

This project is led by Sinergium Biotech, an Argentinian manufacturer, and leverages the World Health Organization (WHO) and the Medicines Patent Pool (MPP) mRNA Technology Transfer Programme. All these factors demand the global influenza vaccine market.

Moreover, the rising demand for the growth of combination vaccine development contributes to the global influenza vaccine market expansion.

High Cost Associated with the Manufacturing Processes

The high cost associated with the manufacturing processes is a significant restraint in the global influenza vaccine market. This constraint arises from a variety of factors that contribute to the overall expenses involved in vaccine production, ultimately impacting both availability and pricing.

Establishing vaccine manufacturing facilities is capital-intensive, with costs ranging from $50 million to $500 million per antigen. The exact amount depends on the complexity of the design, automation, and necessary contamination control measures. Facilities designed to comply with current Good Manufacturing Practices (cGMP) require specialized equipment and infrastructure to ensure product safety and efficacy, driving up initial investment costs.

These costs stem from complex facility requirements, labor expenses, raw material prices, regulatory compliance needs, and lengthy investment recovery periods. Addressing these challenges through innovations in production technology and improved efficiency could help mitigate some of these financial burdens and enhance vaccine accessibility worldwide. Thus, the above factors could be limiting the global influenza vaccine market's potential growth.

Segment Analysis

The global influenza vaccine market is segmented based on product type, category, route of administration, age group, end-user, and region.

Product Type:

The inactivated segment is expected to dominate the global influenza vaccine market share

The inactivated segment holds a major portion of the global influenza vaccine market share and is expected to continue to hold a significant portion of the global influenza vaccine market share during the forecast period.

The inactivated product segment of the global influenza vaccine market is vital for influenza prevention strategies, primarily consisting of inactivated influenza vaccines (IIVs). These vaccines are well-regarded for their safety and effectiveness. Inactivated influenza vaccines are formulated from viruses that have been killed or inactivated, ensuring they cannot cause disease. Typically, these vaccines contain antigens from multiple strains of the influenza virus, protecting against various circulating strains.

Inactivated influenza vaccines (IIVs) are recognized for their robust safety profile and effectiveness in preventing influenza-related illnesses. They stimulate an immune response without the risk of causing the disease, making them suitable for diverse populations, including children and the elderly. The production process for IIVs can be effectively scaled to meet global demand, especially during peak flu seasons. This scalability is crucial for mass vaccination programs, ensuring that sufficient doses are available to protect at-risk populations.

Ongoing research and development efforts focus on enhancing the efficacy of IIVs. Innovations include advancements in adjuvant technology to boost immune responses and efforts to create more strain-specific vaccines that better match circulating viruses. Increased government initiatives promoting flu vaccination contribute to the growth of the IIV segment. Public health campaigns aimed at raising awareness about vaccination benefits further drive demand.

Furthermore, key players in the industry more focus on research activities and the rising number of clinical trials that would propel this segment's growth in the influenza vaccines market. For instance, in September 2024, GSK announced positive headline data from its Phase II trial of a seasonal influenza mRNA vaccine program, indicating promising results for its vaccine candidates against both influenza A and B strains. This trial involved testing various mRNA formulations in healthy adults across two age groups: younger adults (ages 18 to 64) and older adults (ages 65 to 85).

Also, in September 2023, the National Institutes of Health (NIH) launched a Phase 1 clinical trial for an experimental universal influenza vaccine, aiming to provide broad protection against multiple strains of the influenza virus. This initiative is part of ongoing efforts to develop a vaccine that could potentially eliminate the need for annual flu shots and improve public health responses to seasonal and pandemic influenza outbreaks. These factors have solidified the segment's position in the global influenza vaccine market.

Geographical Analysis

North America is expected to hold a significant position in the global influenza vaccine market share

North America holds a substantial position in the global influenza vaccine market and is expected to hold most of the market share.

The prevalence of seasonal influenza in North America is a major driver of vaccine demand. The Centers for Disease Control and Prevention (CDC) reports that there are approximately 3 to 5 million cases of severe influenza globally each year, with a substantial portion occurring in the U.S. This high incidence rate underscores the necessity for effective vaccination strategies to protect public health.

North America boasts a well-established healthcare system that facilitates efficient vaccine distribution and administration. This infrastructure includes advanced healthcare facilities, a robust network of pharmacies, and widespread access to immunization services, ensuring that vaccines are readily available to the population. Strong government initiatives and funding for vaccination programs significantly contribute to market growth. Public health campaigns aimed at increasing awareness about the importance of flu vaccinations help drive demand, particularly among high-risk groups such as the elderly and healthcare workers.

Innovations in vaccine production technology enhance the efficacy and safety of influenza vaccines. The development of quadrivalent vaccines, which protect against four strains of the virus, is particularly noteworthy. Additionally, advancements in digital vaccination monitoring and tracking systems improve vaccine distribution efficiency. The North American market is home to several leading pharmaceutical companies that invest heavily in research and development for influenza vaccines. This competitive landscape fosters rapid product launches and continuous innovation, contributing to the overall growth of the market.

Furthermore, key players in the industry more focus on research activities and the rising number of clinical trials that would propel this segment's growth in the influenza vaccines market in the region. For instance, in June 2024, Moderna, Inc. announced that its Phase 3 trial for the investigational combination vaccine mRNA-1083, which targets both influenza and COVID-19, has successfully met its primary endpoints. The trial demonstrated that this combination vaccine elicited a higher immune response compared to the licensed vaccines currently used for these diseases.

Thus, the above factors are consolidating the region's position as a dominant force in the global influenza vaccine market.

Asia Pacific is growing at the fastest pace in the global influenza vaccine market share

Asia Pacific holds the fastest pace in the global influenza vaccine market and is expected to hold most of the market share.

The increasing prevalence of seasonal influenza outbreaks across Asia-Pacific countries, particularly in densely populated nations like China and India, significantly fuels demand for vaccines. Reports indicate that influenza affects millions annually, underscoring the urgent need for effective vaccination strategies to protect public health. Strong government initiatives aimed at promoting vaccination against influenza play a crucial role in market growth. Many countries in the region are enhancing their public health campaigns to raise awareness about the importance of flu vaccinations, especially among high-risk populations such as children, the elderly, and healthcare workers.

There is a notable increase in investments in healthcare infrastructure across Asia-Pacific, facilitating better vaccine distribution and administration. Improved healthcare facilities and expanded access to immunization services ensure that vaccines are readily available to the population. Innovations in vaccine production technology, including the development of quadrivalent vaccines that protect against four strains of the virus, enhance the efficacy and safety of influenza vaccines. Additionally, advancements in digital health technologies improve vaccine tracking and monitoring systems, contributing to more efficient vaccination campaigns.

The focus on emerging economies within the Asia-Pacific region is driving market growth. Countries like India and South Korea are witnessing increased demand for influenza vaccines due to their large patient pools and rising healthcare infrastructure. These markets benefit from less stringent regulations that facilitate quicker vaccine development and distribution.

Furthermore, key players in the industry product launches that would drive this influenza vaccine market growth. For instance, in March 2024, Cadila Pharmaceuticals announced the launch of its new Cadiflu Tetra vaccine, designed to prevent influenza, a widespread viral infection. This quadrivalent vaccine has received approval from the Drugs Controller General of India (DCGI) for use in both adults and children.

Also, in October 2023, Mylab and the Serum Institute of India (SII) launched Nasovac S4, India's first needle-free nasal influenza vaccine. This innovative vaccine is designed to protect against influenza through a convenient intranasal administration method, making it more accessible and less intimidating, especially for children and individuals with a fear of needles.

Thus, the above factors are consolidating the region's position as the fastest-growing force in the global influenza vaccine market.

Competitive Landscape

The major global players in the influenza vaccine market include Sanofi, GSK plc., Pfizer Inc., AstraZeneca, CSL, Viatris Inc. (Mylan), Bharat Biotech., SINOVAC, Zydus Cadila Healthcare Limited, and Serum Institute of India Pvt. Ltd. among others.

Key Developments

• In September 2024, the FDA approved FluMist, a nasal spray influenza vaccine, for self- or caregiver administration, marking it as the first flu vaccine that does not require administration by a healthcare professional. This approval represents a significant advancement in making influenza vaccination more accessible and convenient for individuals and families.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-world Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global influenza vaccine market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Category
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Age Group
• 3.5. Snippet by End-User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Incidence of Influenza
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost Associated with the Manufacturing Processes
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Inactivated*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Live Attenuated

7. By Category

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 7.1.2. Market Attractiveness Index, By Category
• 7.2. Quadrivalent*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Trivalent

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Injection*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Nasal Spray

9. By Age Group

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 9.1.2. Market Attractiveness Index, By Age Group
• 9.2. Pediatric*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Adults

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospitals*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Hospitals
• 10.4. Specialty Clinics
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
    • 11.2.8.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. U.K.
    • 11.3.8.3. France
    • 11.3.8.4. Spain
    • 11.3.8.5. Italy
    • 11.3.8.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Brazil
    • 11.4.8.2. Argentina
    • 11.4.8.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Sanofi*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. GSK plc.
• 13.3. Pfizer Inc.
• 13.4. AstraZeneca
• 13.5. CSL
• 13.6. Viatris Inc. (Mylan)
• 13.7. Bharat Biotech.
• 13.8. SINOVAC
• 13.9. Zydus Cadila Healthcare Limited
• 13.10. Serum Institute of India Pvt. Ltd.

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us